Correlated Drug Terms (5)

---

	Name (Synonyms)	Correlation
drug2852	Telemedicine follow-up visit Wiki	1.00
drug1400	In-person in clinic follow-up visit Wiki	1.00
drug983	Electronic Health Record Review Wiki	1.00
drug424	Biospecimen Collection Wiki	0.58
drug2312	Questionnaire Administration Wiki	0.38

Correlated MeSH Terms (2)

---

	Name (Synonyms)	Correlation
D003141	Communicable Diseases NIH	0.08
D007239	Infection NIH	0.05

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Will be assayed for severe acute respiratory syndrome (SARS‐CoV‐2) immunoassay, coronavirus (CoV) PepSeq assay, and SARS‐CoV‐2 lenti‐based neutralizing antibody titer.

Measure: Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients

Time: Up to 12 months after enrollment

---

Description: Will naturally be compared to reported data from the other studies. Analysis will focus on demonstrating that the antibody content of donor plasma increases the odds of surviving past day 28. Will also develop a nomogram for the probability of success (alive at day 28), accounting for patient, donor material and donor antibody characteristics measurable covariates.

Measure: All-cause mortality

Time: At day 28 post-CCP infusion

---

Description: Will be examined to see how this relates to the duration of hospitalization.

Measure: Donor antibody levels

Time: Up to 28 days post-CCP infusion

---

Secondary Outcomes

Description: Will be assessed on a 7-point ordinal scale, as recommended by the WHO patient outcome R&D Blueprint Group.

Measure: Incidence of adverse events

Time: Up to 28 days post-CCP infusion

---

Description: Will be assessed on a 7-point ordinal scale. The scale is as follows: Death; Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring low flow supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol RDV administration); Not hospitalized

Measure: CCP recipient outcomes

Time: Up to 28 days post-CCP infusion

---

Other Outcomes

Description: Patient can stay at the hospital for up to 28 days post-CCP infusion

Measure: Duration of hospitalization (days)

Time: Up to 28 days post-CCP infusion

---

Description: Will be assessed on a 7-point ordinal scale.

Measure: Time to clinical improvement (days)

Time: Up to 28 days post-CCP infusion

---